Anti- RF-human FC (IgM), RF-animal FC (IgM), and Anti-Citrullinated peptides (CCP): HCP1, HCP2, VCP1 and VCP2
5-7 Days
ARTH
Addressable LASER Bead Immunoassay (ALBIA)
Semi-Quantitative: HCP1,HCP2, VCP1, VCP2 (IgG): • Negative <100AU/ml • Low positive: 101-120 AU/ml • Medium positive: 121-200 AU/ml • High positive>200 AU/ml RF (IgM) • Negative <30 IU/mL • Low positive: 31-50 IU/mL • Medium positive: 51-100 IU/mL • High positive>100 IU/mL
TBD
With conventional anti-citrullinated protein autoantibody (ACPA) or anti-cyclic citrullinated peptide (CCP) testing missing approximately 10-15% of patients suffering from rheumatoid arthritis, Mitogen’s Arthritis Panel is a comprehensive rheumatoid arthritis test that addresses missed diagnoses. By adding novel autoantibody targets, Mitogen’s Arthritis panel achieves significant improvements in sensitivity for diagnosing rheumatoid arthritis over conventional ACPA testing.
The Arthritis Panel measures six different autoantibodies that are related to rheumatoid arthritis: Rheumatoid Factor: IgM antibodies to human Fc = conventional rheumatoid factor; Rheumatoid Factor: IgM antibodies to rabbit Fc = historic Waaler-Rose RF test; VCP 1: viral citrullinated protein, VCP 2: viral citrullinated protein, HCP 1: histone citrullinated protein, HCP 2: histone citrullinated protein.
With the availability of this test, clinicians should avoid the costs and loss-of-time that inherent with early generations of CCP testing. By solely ordering this panel for suspected RA and known RA patients you gain an increased chance in early detection and missing fewer diagnostic opportunities.
Health Providers & Labs |
Please inquire for pricing |
Direct to Customer / Patient |
Currently not available |